Overcoming Clinical Challenges in BRIC Markets - Brazil
Thomson Reuters Cortellis Competitive Intelligence
Figure 1A: While many still tout the benefits for conducting clinical trials in emerging markets, data from Cortellis finds that drug development in most of the BRIC (Brazil, Russia, India and China) countries is on the decline. Sponsors are largely pulling back or out completely due to increasingly complex regulatory guidelines, corruption, patent challenges, losses to generics, and import/export delays.
Figure 1C: For clinical trials reported in the BRIC countries by phase, Russia and China feature the highest number of unreported phases. Russia edges out the remaining countries on Phase III trials.
Figure 2A: Although improving, Brazil’s regulatory approval process for clinical trials still remains the lengthiest in Latin America and can take anywhere from five to 12 months. ANVISA, the national health surveillance agency for Brazil, operates much like the FDA. The country’s compassionate use program, approved in August 2013, guarantees free orphan drug supply to those who have participated in a Phase III trial and benefitted from the drug. Because the patient population for a rare disease is limited by nature, the sponsor’s Brazilian market for the respective orphan drug may be entirely comprised of its successful Phase III trial patients, negating any profit they may make in the country.
Figure 2B: Overall, trials have declined in Brazil since 2011, however, local companies are filling the gaps, as well as university and government trials. Novartis remains a key player in the country, along with Roche and AstraZeneca. Pfizer, Sanofi, and GSK have decreased their presence.
SOURCE: Thomson Reuters Cortellis Competitive Intelligence
Read the full report here: http://interest.science.thomsonreuters.com/forms/Verify?doc=http://images.info.science.thomsonreuters.biz/Web/ThomsonReutersScience/{569dbe1e-07d1-49ff-9bbe-d9c515a8a526}_BRIC_nations_white_paper_final__201404.pdf&rt=Marketing&sbu=Life%20Sciences&cid=70170000000Ue0T&cn=LS%20-%20201307%20Life%20Sciences%20Connect%20Blog%20Gated%20Forms
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
First Patient Dosed in Phase III Trial of Enhertu as First-Line Treatment for Endometrial Cancer
June 10th 2025In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 study for the treatment of patients with HER2-expressing, mismatch repair proficient primary advanced or recurrent endometrial cancer.
